Cannabis, Low Back Pain, Neuropathic Pain
Conditions
Brief summary
This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or placebo. An analysis will then be determined to assess the risk--benefit ratio of dronabinol and vaporized 3.7% Δ9-THC/5.6% CBD .
Detailed description
The present study is designed to assess whether treatment with vaporized cannabis or dronabinol (oral Δ9-THC) reduces spontaneous and evoked pain more than placebo, and whether there are any differences between the two active treatments in terms of interference with activities of daily living. This study also aims to examine the effects of vaporized whole plant cannabis and dronabinol on mood, neuropsychological function, and psychomimetic side-effects (high, stoned, etc.) compared to placebo and to each other. In addition, we plan to examine the acute effects (after receiving stable treatment for 4 weeks) of vaporized cannabis and dronabinol compared to placebo and each other on driving skills.
Interventions
Administration of vaporized cannabis plus either dronabinol or placebo pill
Administration of vaporized cannabis plus either dronabinol or placebo pill
Administration of vaporized cannabis plus either dronabinol or placebo pill
Sponsors
Study design
Eligibility
Inclusion criteria
Age greater than 18. Presence of chronic low back pain (CLBP) defined as the response to two questions 1) How long has back pain been an ongoing problem for you? 2) How often has low back pain been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1 and a response of at least half the days in the past 6 months to question 2 will define CLBP according to the NIH Task Force on Research Standards for Chronic Low Back Pain. The numerical pain intensity must be greater than 3/10 each day during the one-week observation period. To avoid confounding by concurrent medications, participants will have had a stable analgesic regimen that they will continue throughout the study To obviate residual neuropsychological effects from cannabis exposure, participants will be abstinent from this herbal medicine for 7 days prior to study entry.
Exclusion criteria
Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied. History of traumatic brain injury. Clinically significant or unstable medical condition. Individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD), will be excluded. If warranted clinically, subjects will undergo laboratory evaluation (blood chemistry, electrocardiogram, urinalysis, toxicology screening for confirmation. Females of childbearing potential will undergo pregnancy testing. A positive result on toxicity screening will exclude individuals from participation. A urine drug test that screens for 5 categories of drugs: marijuana (Δ9-THC), cocaine, amphetamines/methamphetamines, opiates, benzodiazepines and phencyclidine (PCP) will be employed. A positive result for opioids and/or THC will not be exclusionary if the patient is receiving a prescription for an opioid and/or THC. Allergy to sesame oil, lactose, or gelatin Vascular disease, especially Raynauld's syndrome, systolic blood pressure \> 170 mm, diastolic blood pressure \> 100 mm Recent injuries to the upper extremity Cognitive impairment, such as Dementia or Alzheimer's Disease Substance Abuse History: The Substance Abuse Module of the Diagnostic Interview Schedule for the Diagnostic and Statistical Manual (DSM)-IV will be administered to exclude individuals with current substance use disorders. Pregnancy as ascertained by a mandatory commercial pregnancy test Past history of suicide attempt. Cannabis can exacerbate pre-existing schizophrenia, and has been linked to an increase in the risk of suicide in such patients. In patients with bipolar disorder, cannabis use has been associated with worsening of manic and psychotic symptoms. Such findings suggest that cannabis is contraindicated in individuals with serious mental health issues, a line of reasoning that will be observed in the present study by excluding patients in the bipolar/schizoaffective/schizophrenic spectrum. Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Beck Depression Inventory (BDI)-II will be used to measure suicidal ideation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numerical Pain Intensity | 8 weeks | The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neuropathic Pain Scale | 8 weeks | The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score. |
| Hopkins Verbal Learning Test | 8 weeks | The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance. |
| Grooved Pegboard Test - Dominant Hand | 8 weeks | The Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3 x 3 metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance. |
| Wechsler Adult Intelligence Scale-III Digit Symbol Test | 8 weeks | The Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance. |
| Profile of Mood States | 8 weeks | This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms. |
| Beck Depression Inventory II | 8 weeks | The Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score. |
| Locally Developed Psychoactive Effect Scale - Good Drug Effect | 6 hours | Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score. |
| Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | 8 weeks | A Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain. The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies. The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS). These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact). |
| Cold Pressor Test - Pain Sensitivity | 8 weeks | Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath. |
| Cannabis Withdrawal Scale - Withdrawal Intensity | Week 8 and Week 10 | The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score. |
| Driving Simulation (Lane Tracking) | 270 minutes | Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy. |
| Driving Simulation (Car Following) | 270 minutes | Car Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation \[0-1\] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy. |
| Locally Developed Psychoactive Effect Scale - High | 6 hours | A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug high will be presented. Range of scores is from 0 to 100. A higher score is a worse score. |
| Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 8, Week 10 | The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score. |
| Cold Pressor Test - Pain Tolerance | 8 weeks | Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath. |
| Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | 8 weeks | The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebos The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill | 44 |
| Dronabinol A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill | 43 |
| Vaporized Cannabis 3.7% THC/5.6% CBD The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill | 44 |
| Total | 131 |
Baseline characteristics
| Characteristic | Dronabinol | Vaporized Cannabis 3.7% THC/5.6% CBD | Placebos | Total |
|---|---|---|---|---|
| Age, Continuous | 48.6 years STANDARD_DEVIATION 13 | 47.4 years STANDARD_DEVIATION 12.3 | 38.8 years STANDARD_DEVIATION 13.7 | 44.9 years STANDARD_DEVIATION 13.6 |
| Education | 13.8 Years STANDARD_DEVIATION 2.4 | 14.6 Years STANDARD_DEVIATION 2.6 | 14.2 Years STANDARD_DEVIATION 2.2 | 14.2 Years STANDARD_DEVIATION 2.39 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 10 Participants | 8 Participants | 11 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants | 36 Participants | 33 Participants | 102 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 7 Participants | 7 Participants | 24 Participants |
| Race (NIH/OMB) More than one race | 3 Participants | 4 Participants | 4 Participants | 11 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants | 1 Participants | 4 Participants | 11 Participants |
| Race (NIH/OMB) White | 22 Participants | 29 Participants | 27 Participants | 78 Participants |
| Sex/Gender, Customized Gender Female | 20 Participants | 20 Participants | 21 Participants | 61 Participants |
| Sex/Gender, Customized Gender Male | 21 Participants | 23 Participants | 23 Participants | 67 Participants |
| Sex/Gender, Customized Gender Transgender (Female to Male) | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Sex/Gender, Customized Gender Transgender (Male to Female) | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 44 | 0 / 43 | 0 / 44 |
| other Total, other adverse events | 30 / 44 | 31 / 43 | 30 / 44 |
| serious Total, serious adverse events | 0 / 44 | 0 / 43 | 0 / 44 |
Outcome results
Numerical Pain Intensity
The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.
Time frame: 8 weeks
Population: There are missing values.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Numerical Pain Intensity | Baseline | 6.03 score on a scale | Standard Deviation 1.65 |
| Placebos | Numerical Pain Intensity | Week 1 | 5.97 score on a scale | Standard Deviation 2.01 |
| Placebos | Numerical Pain Intensity | Week 3 | 5.65 score on a scale | Standard Deviation 1.56 |
| Placebos | Numerical Pain Intensity | Week 5 | 5.47 score on a scale | Standard Deviation 1.77 |
| Placebos | Numerical Pain Intensity | Week 7 | 5.26 score on a scale | Standard Deviation 1.8 |
| Placebos | Numerical Pain Intensity | Week 8 | 5.22 score on a scale | Standard Deviation 1.92 |
| Dronabinol | Numerical Pain Intensity | Week 8 | 4.19 score on a scale | Standard Deviation 2.02 |
| Dronabinol | Numerical Pain Intensity | Baseline | 6.11 score on a scale | Standard Deviation 1.65 |
| Dronabinol | Numerical Pain Intensity | Week 5 | 4.89 score on a scale | Standard Deviation 1.88 |
| Dronabinol | Numerical Pain Intensity | Week 7 | 4.35 score on a scale | Standard Deviation 2.02 |
| Dronabinol | Numerical Pain Intensity | Week 1 | 5.80 score on a scale | Standard Deviation 1.62 |
| Dronabinol | Numerical Pain Intensity | Week 3 | 5.67 score on a scale | Standard Deviation 1.62 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Week 1 | 5.64 score on a scale | Standard Deviation 1.98 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Week 3 | 5.43 score on a scale | Standard Deviation 2.11 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Week 8 | 4.45 score on a scale | Standard Deviation 2.11 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Week 5 | 4.82 score on a scale | Standard Deviation 2.29 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Baseline | 6.24 score on a scale | Standard Deviation 1.87 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Numerical Pain Intensity | Week 7 | 4.72 score on a scale | Standard Deviation 2.23 |
Beck Depression Inventory II
The Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score.
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Beck Depression Inventory II | Week 1 | 7.68 score on a scale | Standard Deviation 8.7 |
| Placebos | Beck Depression Inventory II | Week 3 | 5.76 score on a scale | Standard Deviation 6.59 |
| Placebos | Beck Depression Inventory II | Week 8 | 5.32 score on a scale | Standard Deviation 7.39 |
| Placebos | Beck Depression Inventory II | Baseline | 8.05 score on a scale | Standard Deviation 7.99 |
| Placebos | Beck Depression Inventory II | Week 5 | 5.32 score on a scale | Standard Deviation 7.07 |
| Placebos | Beck Depression Inventory II | Week 7 | 5.50 score on a scale | Standard Deviation 7.63 |
| Dronabinol | Beck Depression Inventory II | Week 5 | 5.52 score on a scale | Standard Deviation 6.28 |
| Dronabinol | Beck Depression Inventory II | Week 7 | 4.36 score on a scale | Standard Deviation 6.49 |
| Dronabinol | Beck Depression Inventory II | Week 8 | 5.25 score on a scale | Standard Deviation 8.11 |
| Dronabinol | Beck Depression Inventory II | Week 1 | 5.61 score on a scale | Standard Deviation 5 |
| Dronabinol | Beck Depression Inventory II | Baseline | 7.81 score on a scale | Standard Deviation 8.26 |
| Dronabinol | Beck Depression Inventory II | Week 3 | 5.26 score on a scale | Standard Deviation 6.81 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Week 8 | 6.06 score on a scale | Standard Deviation 9.62 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Baseline | 7.84 score on a scale | Standard Deviation 8.14 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Week 1 | 5.32 score on a scale | Standard Deviation 6.05 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Week 3 | 5.59 score on a scale | Standard Deviation 7.24 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Week 7 | 6.09 score on a scale | Standard Deviation 8.63 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Beck Depression Inventory II | Week 5 | 6.25 score on a scale | Standard Deviation 8.52 |
Cannabis Withdrawal Scale - Negative Impact of Withdrawal
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score.
Time frame: Week 8, Week 10
Population: Some subjects dropped out before completing the study.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 8 | 8.42 score on a scale | Standard Deviation 22.9 |
| Placebos | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 10 | 8.18 score on a scale | Standard Deviation 24 |
| Dronabinol | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 8 | 3.42 score on a scale | Standard Deviation 7.22 |
| Dronabinol | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 10 | 2.32 score on a scale | Standard Deviation 8.63 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 8 | 10.3 score on a scale | Standard Deviation 24.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cannabis Withdrawal Scale - Negative Impact of Withdrawal | Week 10 | 4.31 score on a scale | Standard Deviation 10.5 |
Cannabis Withdrawal Scale - Withdrawal Intensity
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score.
Time frame: Week 8 and Week 10
Population: Some subjects dropped out before completing the study.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 8 | 13.5 score on a scale | Standard Deviation 23.7 |
| Placebos | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 10 | 12.7 score on a scale | Standard Deviation 25.1 |
| Dronabinol | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 8 | 6.12 score on a scale | Standard Deviation 8.98 |
| Dronabinol | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 10 | 6.32 score on a scale | Standard Deviation 10.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 8 | 12.4 score on a scale | Standard Deviation 25.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cannabis Withdrawal Scale - Withdrawal Intensity | Week 10 | 9.97 score on a scale | Standard Deviation 20.1 |
Cold Pressor Test - Pain Sensitivity
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Time frame: 8 weeks
Population: There were missing values
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Cold Pressor Test - Pain Sensitivity | Pain sensitivity Baseline | 20.0 seconds | Standard Deviation 26.5 |
| Placebos | Cold Pressor Test - Pain Sensitivity | Week 1 | 29.4 seconds | Standard Deviation 36.9 |
| Placebos | Cold Pressor Test - Pain Sensitivity | Week 3 | 21.9 seconds | Standard Deviation 27.5 |
| Placebos | Cold Pressor Test - Pain Sensitivity | Week 5 | 20.9 seconds | Standard Deviation 28.4 |
| Placebos | Cold Pressor Test - Pain Sensitivity | Week 7 | 20.4 seconds | Standard Deviation 26.6 |
| Placebos | Cold Pressor Test - Pain Sensitivity | Week 8 | 21.1 seconds | Standard Deviation 24.3 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Week 8 | 15.8 seconds | Standard Deviation 11 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Pain sensitivity Baseline | 18.3 seconds | Standard Deviation 21.8 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Week 5 | 20.4 seconds | Standard Deviation 24.8 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Week 7 | 21.5 seconds | Standard Deviation 25.7 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Week 1 | 23.0 seconds | Standard Deviation 31.6 |
| Dronabinol | Cold Pressor Test - Pain Sensitivity | Week 3 | 18.8 seconds | Standard Deviation 22.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Week 1 | 20.5 seconds | Standard Deviation 29.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Week 3 | 21.0 seconds | Standard Deviation 23.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Week 8 | 23.9 seconds | Standard Deviation 30.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Week 5 | 24.7 seconds | Standard Deviation 28.8 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Pain sensitivity Baseline | 26.3 seconds | Standard Deviation 30.1 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Sensitivity | Week 7 | 20.9 seconds | Standard Deviation 24.7 |
Cold Pressor Test - Pain Tolerance
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Time frame: 8 weeks
Population: There were some missing values
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Cold Pressor Test - Pain Tolerance | Baseline | 47.2 seconds | Standard Deviation 42 |
| Placebos | Cold Pressor Test - Pain Tolerance | Week 1 | 50.5 seconds | Standard Deviation 40.4 |
| Placebos | Cold Pressor Test - Pain Tolerance | Week 3 | 46.2 seconds | Standard Deviation 38 |
| Placebos | Cold Pressor Test - Pain Tolerance | Week 5 | 41.4 seconds | Standard Deviation 39.5 |
| Placebos | Cold Pressor Test - Pain Tolerance | Week 7 | 61.7 seconds | Standard Deviation 53.8 |
| Placebos | Cold Pressor Test - Pain Tolerance | Week 8 | 37.9 seconds | Standard Deviation 35 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Week 8 | 37.5 seconds | Standard Deviation 32.4 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Baseline | 40.6 seconds | Standard Deviation 34.1 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Week 5 | 43.6 seconds | Standard Deviation 41.5 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Week 7 | 44.2 seconds | Standard Deviation 40.4 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Week 1 | 44.8 seconds | Standard Deviation 46.9 |
| Dronabinol | Cold Pressor Test - Pain Tolerance | Week 3 | 40.0 seconds | Standard Deviation 34.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Week 1 | 60.9 seconds | Standard Deviation 48.8 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Week 3 | 64.3 seconds | Standard Deviation 49.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Week 8 | 62.3 seconds | Standard Deviation 45.8 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Week 5 | 60.7 seconds | Standard Deviation 45.9 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Baseline | 58.3 seconds | Standard Deviation 46 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Cold Pressor Test - Pain Tolerance | Week 7 | 54.7 seconds | Standard Deviation 42.9 |
Driving Simulation (Car Following)
Car Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation \[0-1\] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Time frame: 270 minutes
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Driving Simulation (Car Following) | After First Dose 230 minutes | 0.72 score on a scale | Standard Deviation 0.24 |
| Placebos | Driving Simulation (Car Following) | After First Dose 100 minutes | 0.59 score on a scale | Standard Deviation 0.33 |
| Placebos | Driving Simulation (Car Following) | Pre Dose | 0.70 score on a scale | Standard Deviation 0.17 |
| Placebos | Driving Simulation (Car Following) | After First Dose 30 minutes | 0.75 score on a scale | Standard Deviation 0.13 |
| Placebos | Driving Simulation (Car Following) | After Second Dose 30 minutes | 0.74 score on a scale | Standard Deviation 0.19 |
| Dronabinol | Driving Simulation (Car Following) | After First Dose 100 minutes | 0.68 score on a scale | Standard Deviation 0.2 |
| Dronabinol | Driving Simulation (Car Following) | Pre Dose | 0.62 score on a scale | Standard Deviation 0.2 |
| Dronabinol | Driving Simulation (Car Following) | After First Dose 30 minutes | 0.71 score on a scale | Standard Deviation 0.2 |
| Dronabinol | Driving Simulation (Car Following) | After First Dose 230 minutes | 0.60 score on a scale | Standard Deviation 0.27 |
| Dronabinol | Driving Simulation (Car Following) | After Second Dose 30 minutes | 0.68 score on a scale | Standard Deviation 0.26 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Car Following) | After Second Dose 30 minutes | 0.60 score on a scale | Standard Deviation 0.22 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Car Following) | After First Dose 230 minutes | 0.62 score on a scale | Standard Deviation 0.25 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Car Following) | Pre Dose | 0.49 score on a scale | Standard Deviation 0.29 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Car Following) | After First Dose 100 minutes | 0.56 score on a scale | Standard Deviation 0.22 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Car Following) | After First Dose 30 minutes | 0.61 score on a scale | Standard Deviation 0.23 |
Driving Simulation (Lane Tracking)
Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Time frame: 270 minutes
Population: There are some missing values
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Driving Simulation (Lane Tracking) | After First Dose 230 minutes | 1.31 score on a scale | Standard Deviation 0.57 |
| Placebos | Driving Simulation (Lane Tracking) | After First Dose 100 minutes | 1.12 score on a scale | Standard Deviation 0.57 |
| Placebos | Driving Simulation (Lane Tracking) | Pre Dose | 0.75 score on a scale | Standard Deviation 0.18 |
| Placebos | Driving Simulation (Lane Tracking) | After First Dose 30 minutes | 1.18 score on a scale | Standard Deviation 0.43 |
| Placebos | Driving Simulation (Lane Tracking) | After Second Dose 30 minutes | 1.13 score on a scale | Standard Deviation 0.47 |
| Dronabinol | Driving Simulation (Lane Tracking) | After First Dose 100 minutes | 1.78 score on a scale | Standard Deviation 0.87 |
| Dronabinol | Driving Simulation (Lane Tracking) | Pre Dose | 1.28 score on a scale | Standard Deviation 0.65 |
| Dronabinol | Driving Simulation (Lane Tracking) | After First Dose 30 minutes | 1.41 score on a scale | Standard Deviation 0.61 |
| Dronabinol | Driving Simulation (Lane Tracking) | After First Dose 230 minutes | 1.51 score on a scale | Standard Deviation 0.76 |
| Dronabinol | Driving Simulation (Lane Tracking) | After Second Dose 30 minutes | 1.65 score on a scale | Standard Deviation 0.79 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Lane Tracking) | After Second Dose 30 minutes | 1.24 score on a scale | Standard Deviation 0.39 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Lane Tracking) | After First Dose 230 minutes | 1.11 score on a scale | Standard Deviation 0.25 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Lane Tracking) | Pre Dose | 1.14 score on a scale | Standard Deviation 0.41 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Lane Tracking) | After First Dose 100 minutes | 1.21 score on a scale | Standard Deviation 0.35 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Driving Simulation (Lane Tracking) | After First Dose 30 minutes | 1.12 score on a scale | Standard Deviation 0.32 |
Grooved Pegboard Test - Dominant Hand
The Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3 x 3 metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance.
Time frame: 8 weeks
Population: There were some missing data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Grooved Pegboard Test - Dominant Hand | Baseline | 63.7 seconds | Standard Deviation 10.6 |
| Placebos | Grooved Pegboard Test - Dominant Hand | Week 1 | 60.7 seconds | Standard Deviation 9.83 |
| Placebos | Grooved Pegboard Test - Dominant Hand | Week 3 | 61.1 seconds | Standard Deviation 14.1 |
| Placebos | Grooved Pegboard Test - Dominant Hand | Week 5 | 59.9 seconds | Standard Deviation 14.8 |
| Placebos | Grooved Pegboard Test - Dominant Hand | Week 7 | 59.7 seconds | Standard Deviation 13.6 |
| Placebos | Grooved Pegboard Test - Dominant Hand | Week 8 | 60.8 seconds | Standard Deviation 18.5 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Week 8 | 69.2 seconds | Standard Deviation 27.6 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Baseline | 73.4 seconds | Standard Deviation 21.1 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Week 5 | 69.0 seconds | Standard Deviation 23.3 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Week 7 | 68.7 seconds | Standard Deviation 24.9 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Week 1 | 69.5 seconds | Standard Deviation 23.8 |
| Dronabinol | Grooved Pegboard Test - Dominant Hand | Week 3 | 63.1 seconds | Standard Deviation 10.9 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Week 1 | 64.5 seconds | Standard Deviation 13.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Week 3 | 64.1 seconds | Standard Deviation 11.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Week 8 | 61.7 seconds | Standard Deviation 12.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Week 5 | 61.7 seconds | Standard Deviation 12.1 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Baseline | 69.1 seconds | Standard Deviation 14.4 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Grooved Pegboard Test - Dominant Hand | Week 7 | 62.5 seconds | Standard Deviation 13.3 |
Hopkins Verbal Learning Test
The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance.
Time frame: 8 weeks
Population: Some subjects dropped out before completing the study.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Hopkins Verbal Learning Test | Week 7 | 24.3 Number of correct words | Standard Deviation 4 |
| Placebos | Hopkins Verbal Learning Test | Week 8 | 24.0 Number of correct words | Standard Deviation 4.16 |
| Placebos | Hopkins Verbal Learning Test | Week 5 | 25.6 Number of correct words | Standard Deviation 3.84 |
| Placebos | Hopkins Verbal Learning Test | Week 3 | 22.9 Number of correct words | Standard Deviation 3.74 |
| Placebos | Hopkins Verbal Learning Test | Baseline | 24.1 Number of correct words | Standard Deviation 5.24 |
| Placebos | Hopkins Verbal Learning Test | Week 1 | 24.0 Number of correct words | Standard Deviation 4.78 |
| Dronabinol | Hopkins Verbal Learning Test | Baseline | 23.7 Number of correct words | Standard Deviation 5.21 |
| Dronabinol | Hopkins Verbal Learning Test | Week 7 | 24.7 Number of correct words | Standard Deviation 4.78 |
| Dronabinol | Hopkins Verbal Learning Test | Week 1 | 23.3 Number of correct words | Standard Deviation 4.44 |
| Dronabinol | Hopkins Verbal Learning Test | Week 5 | 24.0 Number of correct words | Standard Deviation 4.9 |
| Dronabinol | Hopkins Verbal Learning Test | Week 8 | 24.5 Number of correct words | Standard Deviation 4.68 |
| Dronabinol | Hopkins Verbal Learning Test | Week 3 | 23.6 Number of correct words | Standard Deviation 5.04 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Week 8 | 24.8 Number of correct words | Standard Deviation 5.53 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Baseline | 24.4 Number of correct words | Standard Deviation 4.9 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Week 1 | 24.0 Number of correct words | Standard Deviation 4.44 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Week 3 | 22.8 Number of correct words | Standard Deviation 4.08 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Week 5 | 24.6 Number of correct words | Standard Deviation 4.55 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Hopkins Verbal Learning Test | Week 7 | 23.8 Number of correct words | Standard Deviation 4.99 |
Locally Developed Psychoactive Effect Scale - Good Drug Effect
Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score.
Time frame: 6 hours
Population: There are some missing values
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 1 hour | 14.2 score on a scale | Standard Deviation 24.4 |
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 2 hours | 14.0 score on a scale | Standard Deviation 23.8 |
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 3 hours | 5.88 score on a scale | Standard Deviation 14.3 |
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 4 hours | 7.43 score on a scale | Standard Deviation 15.9 |
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 5 hours | 11.6 score on a scale | Standard Deviation 28.5 |
| Placebos | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 6 hours | 10.7 score on a scale | Standard Deviation 27 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 6 hours | 32.4 score on a scale | Standard Deviation 41.4 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 1 hour | 19.1 score on a scale | Standard Deviation 34.3 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 4 hours | 36.3 score on a scale | Standard Deviation 42.8 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 5 hours | 29.7 score on a scale | Standard Deviation 41.9 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 2 hours | 33.5 score on a scale | Standard Deviation 38.5 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 3 hours | 33.2 score on a scale | Standard Deviation 44.1 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 2 hours | 45.7 score on a scale | Standard Deviation 31.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 3 hours | 27.5 score on a scale | Standard Deviation 29.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 6 hours | 40.4 score on a scale | Standard Deviation 35.9 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 4 hours | 37.0 score on a scale | Standard Deviation 37.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 1 hour | 58.8 score on a scale | Standard Deviation 32.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - Good Drug Effect | After dose 5 hours | 44.4 score on a scale | Standard Deviation 34.3 |
Locally Developed Psychoactive Effect Scale - High
A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug high will be presented. Range of scores is from 0 to 100. A higher score is a worse score.
Time frame: 6 hours
Population: There are some missing values
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 1 hour | 5.38 score on a scale | Standard Deviation 12.2 |
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 2 hours | 5.75 score on a scale | Standard Deviation 14.7 |
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 3 hours | 5.56 score on a scale | Standard Deviation 13.2 |
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 4 hours | 4.00 score on a scale | Standard Deviation 7 |
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 5 hours | 1.75 score on a scale | Standard Deviation 1.83 |
| Placebos | Locally Developed Psychoactive Effect Scale - High | After dose 6 hours | 1.71 score on a scale | Standard Deviation 3.4 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 6 hours | 24.8 score on a scale | Standard Deviation 38.7 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 1 hour | 14.9 score on a scale | Standard Deviation 31.5 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 4 hours | 28.6 score on a scale | Standard Deviation 32.5 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 5 hours | 21.5 score on a scale | Standard Deviation 36.9 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 2 hours | 25.8 score on a scale | Standard Deviation 38.1 |
| Dronabinol | Locally Developed Psychoactive Effect Scale - High | After dose 3 hours | 31.8 score on a scale | Standard Deviation 40.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 2 hours | 36.7 score on a scale | Standard Deviation 27.1 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 3 hours | 20.5 score on a scale | Standard Deviation 22.5 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 6 hours | 31.7 score on a scale | Standard Deviation 30.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 4 hours | 29.5 score on a scale | Standard Deviation 32.8 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 1 hour | 49.8 score on a scale | Standard Deviation 30.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Locally Developed Psychoactive Effect Scale - High | After dose 5 hours | 43.9 score on a scale | Standard Deviation 32.8 |
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis.
Time frame: 8 weeks
Population: There were missing values.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 7 | 1.61 score on a scale | Standard Deviation 2.41 |
| Placebos | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 5 | 1.31 score on a scale | Standard Deviation 2.19 |
| Placebos | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 1 | 1.59 score on a scale | Standard Deviation 2.02 |
| Placebos | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 3 | 1.63 score on a scale | Standard Deviation 2.11 |
| Placebos | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 8 | 1.11 score on a scale | Standard Deviation 1.95 |
| Dronabinol | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 5 | 2.93 score on a scale | Standard Deviation 2.51 |
| Dronabinol | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 1 | 1.81 score on a scale | Standard Deviation 1.72 |
| Dronabinol | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 3 | 2.47 score on a scale | Standard Deviation 2.21 |
| Dronabinol | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 7 | 2.46 score on a scale | Standard Deviation 2.38 |
| Dronabinol | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 8 | 2.29 score on a scale | Standard Deviation 2.34 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 8 | 2.31 score on a scale | Standard Deviation 2.36 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 7 | 2.80 score on a scale | Standard Deviation 2.47 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 1 | 2.31 score on a scale | Standard Deviation 2.28 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 5 | 2.67 score on a scale | Standard Deviation 2.41 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Marijuana Subscale (M-scale) of the Addiction Research Center Inventory | Week 3 | 2.33 score on a scale | Standard Deviation 1.91 |
Neuropathic Pain Scale
The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score.
Time frame: 8 weeks
Population: Some subjects dropped out before completing the study.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Neuropathic Pain Scale | Week 1 | 40.4 score on a scale | Standard Deviation 16.7 |
| Placebos | Neuropathic Pain Scale | Week 5 | 35.1 score on a scale | Standard Deviation 16.4 |
| Placebos | Neuropathic Pain Scale | Week 3 | 37.0 score on a scale | Standard Deviation 17.2 |
| Placebos | Neuropathic Pain Scale | Baseline | 45.9 score on a scale | Standard Deviation 15.2 |
| Placebos | Neuropathic Pain Scale | Week 8 | 34.6 score on a scale | Standard Deviation 18.3 |
| Placebos | Neuropathic Pain Scale | Week 7 | 36.0 score on a scale | Standard Deviation 17.8 |
| Dronabinol | Neuropathic Pain Scale | Week 3 | 34.6 score on a scale | Standard Deviation 13.6 |
| Dronabinol | Neuropathic Pain Scale | Baseline | 45.1 score on a scale | Standard Deviation 13.5 |
| Dronabinol | Neuropathic Pain Scale | Week 1 | 38.9 score on a scale | Standard Deviation 12 |
| Dronabinol | Neuropathic Pain Scale | Week 5 | 30.8 score on a scale | Standard Deviation 14.8 |
| Dronabinol | Neuropathic Pain Scale | Week 7 | 29.6 score on a scale | Standard Deviation 14.8 |
| Dronabinol | Neuropathic Pain Scale | Week 8 | 28.2 score on a scale | Standard Deviation 16.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Baseline | 48.3 score on a scale | Standard Deviation 15.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Week 8 | 33.2 score on a scale | Standard Deviation 20.4 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Week 7 | 33.4 score on a scale | Standard Deviation 19.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Week 1 | 42.3 score on a scale | Standard Deviation 15.9 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Week 3 | 39.2 score on a scale | Standard Deviation 19.1 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Neuropathic Pain Scale | Week 5 | 37.5 score on a scale | Standard Deviation 17.6 |
Profile of Mood States
This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms.
Time frame: 8 weeks
Population: There were some missing data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Profile of Mood States | Baseline | 57.3 score on a scale | Standard Deviation 32 |
| Placebos | Profile of Mood States | Week 1 | 51.5 score on a scale | Standard Deviation 36.9 |
| Placebos | Profile of Mood States | Week 3 | 48.6 score on a scale | Standard Deviation 30.6 |
| Placebos | Profile of Mood States | Week 5 | 46.3 score on a scale | Standard Deviation 27.2 |
| Placebos | Profile of Mood States | Week 7 | 45.5 score on a scale | Standard Deviation 27.3 |
| Placebos | Profile of Mood States | Week 8 | 42.5 score on a scale | Standard Deviation 30.9 |
| Dronabinol | Profile of Mood States | Week 8 | 41.0 score on a scale | Standard Deviation 28.5 |
| Dronabinol | Profile of Mood States | Baseline | 53.8 score on a scale | Standard Deviation 31.5 |
| Dronabinol | Profile of Mood States | Week 5 | 40.0 score on a scale | Standard Deviation 22.7 |
| Dronabinol | Profile of Mood States | Week 7 | 37.7 score on a scale | Standard Deviation 23.7 |
| Dronabinol | Profile of Mood States | Week 1 | 46.2 score on a scale | Standard Deviation 23.6 |
| Dronabinol | Profile of Mood States | Week 3 | 42.9 score on a scale | Standard Deviation 27.4 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Week 1 | 41.5 score on a scale | Standard Deviation 22.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Week 3 | 38.8 score on a scale | Standard Deviation 23.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Week 8 | 39.7 score on a scale | Standard Deviation 26.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Week 5 | 38.8 score on a scale | Standard Deviation 22 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Baseline | 53.2 score on a scale | Standard Deviation 30.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Profile of Mood States | Week 7 | 44.2 score on a scale | Standard Deviation 29.2 |
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
A Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain. The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies. The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS). These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact).
Time frame: 8 weeks
Population: There were some missing data
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Baseline | 21.6 score on a scale | Standard Deviation 7.29 |
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 1 | 18.5 score on a scale | Standard Deviation 8.97 |
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 3 | 17.2 score on a scale | Standard Deviation 7.4 |
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 5 | 16.3 score on a scale | Standard Deviation 7.7 |
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 7 | 16.2 score on a scale | Standard Deviation 7.42 |
| Placebos | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 8 | 15.9 score on a scale | Standard Deviation 9.06 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 8 | 15.8 score on a scale | Standard Deviation 8.53 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Baseline | 22.5 score on a scale | Standard Deviation 6.46 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 5 | 16.9 score on a scale | Standard Deviation 6.93 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 7 | 15.1 score on a scale | Standard Deviation 7.17 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 1 | 19.9 score on a scale | Standard Deviation 6.48 |
| Dronabinol | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 3 | 18.1 score on a scale | Standard Deviation 7.44 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 1 | 20.3 score on a scale | Standard Deviation 8.08 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 3 | 19.2 score on a scale | Standard Deviation 9.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 8 | 15.8 score on a scale | Standard Deviation 10.3 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 5 | 16.6 score on a scale | Standard Deviation 9.18 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Baseline | 23.1 score on a scale | Standard Deviation 7.03 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain) | Week 7 | 16.1 score on a scale | Standard Deviation 9.88 |
Wechsler Adult Intelligence Scale-III Digit Symbol Test
The Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance.
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Baseline | 80.3 number of correct symbols | Standard Deviation 14.9 |
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 1 | 84.8 number of correct symbols | Standard Deviation 17.2 |
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 3 | 88.9 number of correct symbols | Standard Deviation 17.5 |
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 5 | 90.0 number of correct symbols | Standard Deviation 19.7 |
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 7 | 88.4 number of correct symbols | Standard Deviation 20.9 |
| Placebos | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 8 | 84.8 number of correct symbols | Standard Deviation 22.6 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 8 | 79.3 number of correct symbols | Standard Deviation 21.9 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Baseline | 69.6 number of correct symbols | Standard Deviation 17.2 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 5 | 79.2 number of correct symbols | Standard Deviation 20.9 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 7 | 79.8 number of correct symbols | Standard Deviation 19.8 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 1 | 73.5 number of correct symbols | Standard Deviation 19.3 |
| Dronabinol | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 3 | 75.6 number of correct symbols | Standard Deviation 18.2 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 1 | 78.3 number of correct symbols | Standard Deviation 16.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 3 | 77.6 number of correct symbols | Standard Deviation 19.7 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 8 | 87.3 number of correct symbols | Standard Deviation 18.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 5 | 83.1 number of correct symbols | Standard Deviation 18.8 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Baseline | 72.2 number of correct symbols | Standard Deviation 15.6 |
| Vaporized Cannabis 3.7% THC/5.6% CBD | Wechsler Adult Intelligence Scale-III Digit Symbol Test | Week 7 | 81.0 number of correct symbols | Standard Deviation 21.3 |